Rasagiline has a neuroprotective effect on RGC survival in glaucomatous rats

Article

Rasagiline can be used as a systematic treatment to improve chances of retinal ganglion cell (RGC) survival in glaucomatous eyes

Rasagiline can be used as a systematic treatment to improve chances of retinal ganglion cell (RGC) survival in glaucomatous eyes, according to a study featured in the Journal of Glaucoma.

A team led by Dr Hani Levkovitch-Verbin, Goldschleger Eye Institute, Tel Hashomer, Israel, injected the anti-Parkison disease drug into Wistar rats. The rats were split into a 3mg/kg, 0.5 mg/kg group and a saline-treated group.

Intraocular pressure (IOP) was measured before and after the injections and weekly for seven weeks. All the rats were killed and their eyes were enucleated and the retinas were set up as whole mounts. Ten days before enucleation fluoro-gold was injected into the superior colliculus. To calulate RGC survival the remaining labelled RGCs were counted in a masked way.

All of the rats presented with a significantly higher IOP and RGC damage. The mean RGC survival rate was 43±8% in the rasagiline 3 mg/kg-treated group and 43±9% in the rasagiline 0.5 mg/kg-treated group. This was compared with 23%±4% in the saline-treated (control) group.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.